The 10 drugs that cost Medicare Part D the most in 2018, according to a Moody’s Investors Service report:
- Eliquis (Bristol-Myers Squibb/Pfizer) — $4.99 billion
- Revlimid (Bristol-Myers Squibb) — $4.06 billion
- Xarelto (Johnson & Johnson/ Bayer) — $3.36 billion
- Januvia (Merck) — $3.23 billion
- Lyrica (Pfizer) — $2.95 billion
- Advair Diskus (GlaxoSmithKline) — $2.39 billion
- Humira Pen (AbbVie) — $2.39 billion
- Lantus Solostar (Sanofi) — $2.37 billion
- Imbruvica (AbbVie/Johnson & Johnson) — $1.87 billion
- Symbicort (AstraZeneca) — $1.75 billion
More articles on pharmacy:
CVS offering emergency prescriptions in Puerto Rico
IPO of joint venture with Pfizer not discussed, GlaxoSmithKline says
Civica Rx inks deal to create its own drugs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
